All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs

Eli Lilly’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA), orforglipron, has proven its efficacy as a maintenance therapy in patients…
FDA approves meningioma label warning on Pfizer’s contraceptive injection

The US Food and Drug Administration (FDA) has approved a label change to Pfizer’s injectable contraceptive, Depo-Provera (medroxyprogesterone acetate), which…
GSK obtains FDA approval for Exdensur in severe asthma

GSK has secured approval from the US Food and Drug Administration (FDA) for its severe asthma add-on maintenance therapy, Exdensur…
Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures

Pfizer has set its FY2026 profit forecast below analyst estimates, blaming projected losses on waning Covid vaccine sales and the…
High-value oncology deals drive China’s drug licensing boom

As 2025 draws to a close, China’s meteoric rise in the innovative medicines segment has undeniably captured the attention of…

J&J gains label expansion approval for Akeega in mCSPC

Johnson & Johnson (J&J) has secured a US label expansion for its next-generation oncology combination, Akeega, in breast cancer gene…
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn

Novartis has teamed up with AI-led biotech Relation Therapeutics in a deal worth up to approximately $1.7bn to discover and…
UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments

The UK Government has cut its innovative medicine rebate rate by more than a third in a move likely to…
Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility

American pharmaceutical giant Eli Lilly has tapped Huntsville, Alabama, as the location for its third orforglipron manufacturing facility. Set to…
CDC panel votes to revoke newborn hepatitis B vaccine recommendation

After a fiery panel meeting, the US Centres for Disease Control’s (CDC) vaccine committee has voted to revoke its routine…